Sellas Life Sciences Draws Heavy Institutional Interest as Its Defining Leukemia Trial Nears the Decisive Phase

Sellas Life Sciences hits 80 survival events in Phase 3 REGAL trial, sparking a 360% YTD rally; Vanguard and Jefferies boost stakes amid strong cash position.

The wait for a single clinical milestone has transformed Sellas Life Sciences into one of the most closely watched small-cap biotechs on the market. With the Phase 3 REGAL trial for Galinpepimut-S in acute myeloid leukemia having now recorded its 80th survival event, the company has formally entered the quiet period that precedes database lock and the final efficacy analysis. For investors, that threshold marks the beginning of the endgame: the next meaningful update could come in the form of regulatory submission data.

That anticipation has not gone unnoticed by institutional money managers. Vanguard disclosed in a filing with US regulators that it holds 9.67 million shares, a passive stake of 5.19 percent, based on its position as of June 30. Jefferies, meanwhile, opened a fresh position of roughly 200,000 shares on August 18, valued at close to $3 million — a purchase that forms part of a broader wave of institutional accumulation reported in recent days.

A Sector Rally Adds Fuel to the Fire

The stock closed Friday at EUR 13.05, up 13 percent on the day. Over seven trading sessions, the gain stands at 18 percent; over 30 days, it reaches 21 percent. Since the start of the year, the share price has climbed an extraordinary 360 percent.

Part of that momentum traces back to a sector-wide surge between August 19 and 21, when positive Phase 3 data from a Moderna and Merck cancer vaccine lifted the entire field of immunotherapy-focused biotechs. Sellas rode that wave disproportionately, as investors drew parallels between those results and the company's own GPS program. Notably, Friday's advance occurred without any company-specific news release — a sign of how much of the current move is being driven by expectation rather than fresh catalysts.

The Financial Position Behind the Run

The company's second-quarter results, released roughly two weeks ago, have also contributed to the rally; the stock has added 28.6 percent since that report. The numbers themselves tell a familiar biotech story: a net loss that widened to $9.6 million in Q2, up from $6.6 million in the year-ago period. Research spending climbed to $6.3 million, which management attributed to preparations for a potential regulatory filing for GPS, including manufacturing capacity for eventual commercialization.

What gives the company breathing room is its balance sheet. Cash and equivalents stood at $138.3 million as of June 30, up sharply from $71.8 million at the end of 2025. The increase was fueled largely by $82.9 million in proceeds from exercised warrants — a cushion that should carry the company through to potential approval-related milestones without an immediate need to tap capital markets.

A Second Program in the Wings

While REGAL commands the spotlight, Sellas is quietly advancing a second candidate. SLS009, also known as Tambiciclib, is being tested in a Phase 2 study for newly diagnosed AML patients in the first-line setting. Enrollment has reached 28 of a planned 80 patients, with topline data expected in the fourth quarter of 2026. Preclinical work has also shown activity in pancreatic cancer cells resistant to RAS inhibitors, along with synergistic effects when combined with RAS inhibition — an early signal that could broaden the program's scope.

CEO Angelos Stergiou used a Monday appearance to highlight a pediatric leukemia study that he argued strengthens the scientific case for Galinpepimut-S, an effort that media reports framed as part of the company's positioning ahead of the quiet period.

Not Everything Is Running Smoothly

The company's Chinese partner, 3D Medicines, was awarded $1 million in cost reimbursement following an arbitration proceeding over disputed milestone payments related to GPS — a reminder that not all aspects of the partnership have gone according to plan.

Valuation metrics, meanwhile, suggest the market is pricing in considerable success. Automated analyses point to a price-to-book ratio of roughly 19.7 times, far above the industry average of 2.5. The stock currently trades 26 percent above its 50-day moving average of EUR 10.33 and sits 14 percent below its 52-week high of EUR 15.25. For longer-term holders, the gains are even more striking: the shares are up 757 percent over the past year, and the distance from the 200-day average stands at 139 percent — a measure of just how far the valuation has stretched from its historical norms.

The question that now hangs over the stock is the one that defines every binary biotech bet: whether the underlying data will ultimately justify the price the market has already assigned. With the 80th event now recorded, the answer will come when the numbers speak for themselves.